Robotic-assisted Extended Thymectomy for Large Resectable Thymoma: 21 Years' Experience
Luyu Huang,Zhongmin Li,Feng Li,Hongbin Zhang,Wenqiang Zhang,Aron Elsner,Julia Strauchmann,Marco Nicolas Andreas,Tomasz Dziodzio,Aina Lask,Jens Neudecker,Mahmoud Ismail,Daipeng Xie,Haiyu Zhou,Andreas Meisel,Jens-C Rueckert
DOI: https://doi.org/10.1016/j.jtcvs.2024.08.005
2024-08-17
Abstract:Objective: This study aims to evaluate the perioperative and midterm oncological outcomes of robotic-assisted thoracic surgery (RATS) extended thymectomy for patients with large resectable thymomas compared to small thymomas. Methods: This retrospective single-center study included 204 thymoma patients who underwent RATS extended thymectomy between January 2003 and February 2024. Patients were divided into two groups based on the thymoma size (5cm threshold). Results: The study comprised 114 patients (55.9%) in the small thymoma (ST) group and 90 patients (44.1%) in the large thymoma (LT) group. No significant differences were found between the groups regarding gender, age, proportion of elderly patients, or pathologic high-risk classifications. Apart from a longer operative time (p=0.009) in the LT group, no differences were observed between the two groups regarding surgical parameters and postoperative outcomes. No deaths occurred within 30 days in either group. During a median follow-up of 61.0 months (95% CI: 48.96-73.04), four patients experienced recurrence (1.96%). No significant differences in the five-year overall survival (OS) rate (p=0.25) or recurrence-free survival (RFS) rate (p=0.43) were observed between groups. Conclusions: RATS extended thymectomy is technically feasible, safe, and effective for treating large resectable thymomas. Moreover, midterm outcomes for patients with completely resected large thymomas were comparable to those with small thymomas during a median follow-up period of up to five years.